Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Neurocrine Biosciences Inc (NBIX)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Neurocrine Biosciences Inc.
(See page 1 of this report.) Table 2 shows the detailed insider transactions.
This company's CIK number is 914475.
Total stock buying since 2015: $0.
Total stock sales since 2015: $574,950,313.
Total stock option exercises since 2015: $118,701,672.
Table 3. Detailed insider trading at Neurocrine Biosciences Inc (NBIX) , Part 6
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2016-05-16 | Pops Richard F (Director) | Option Ex | 15,000 | 3.07 | 46,050 |
| 2016-05-06 | Lyons Gary A (Director) | Option Ex | 15,000 | 3.07 | 46,050 |
| 2016-05-03 | Nevinny Corinne H (Director) | Option Ex | 15,000 | 3.07 | 46,050 |
| 2016-04-14 | Sherwin Stephen A (Director) | Option Ex | 15,000 | 3.07 | 46,050 |
| 2016-04-11 | Gano Kyle (Chief Business Development Officer) | Sale | 41,770 | 43.77 | 1,828,272 |
| 2016-04-11 | Gano Kyle (Chief Business Development Officer) | Option Ex | 41,770 | 5.76 | 240,595 |
| 2016-04-06 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 25,000 | 45.00 | 1,125,000 |
| 2016-02-10 | Mollica Joseph A (Director) | Option Ex | 20,000 | 3.07 | 61,400 |
| 2016-02-03 | Gano Kyle (Chief Business Development Officer) | Sale | 1,375 | 37.98 | 52,222 |
| 2016-02-03 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 1,375 | 37.98 | 52,222 |
| 2016-02-03 | Bozigian Haig P. (Chief Development Officer) | Sale | 1,375 | 38.13 | 52,428 |
| 2016-02-03 | Coughlin Timothy P (Chief Financial Officer) | Sale | 1,500 | 38.06 | 57,090 |
| 2016-02-03 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 1,500 | 38.01 | 57,015 |
| 2016-02-03 | Gorman Kevin Charles (President and CEO) | Sale | 3,125 | 38.04 | 118,875 |
| 2016-01-19 | Gano Kyle (Chief Business Development Officer) | Sale | 1,625 | 46.84 | 76,115 |
| 2016-01-19 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 1,625 | 46.76 | 75,985 |
| 2016-01-19 | Bozigian Haig P. (Chief Development Officer) | Sale | 1,625 | 46.77 | 76,001 |
| 2016-01-19 | Coughlin Timothy P (Chief Financial Officer) | Sale | 1,750 | 46.69 | 81,707 |
| 2016-01-19 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 1,750 | 46.77 | 81,847 |
| 2016-01-19 | Gorman Kevin Charles (President and CEO) | Sale | 3,750 | 46.70 | 175,125 |
| 2016-01-11 | Gano Kyle (Chief Business Development Officer) | Sale | 1,250 | 44.23 | 55,287 |
| 2016-01-11 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 1,625 | 44.21 | 71,841 |
| 2016-01-11 | Bozigian Haig P. (Chief Development Officer) | Sale | 1,625 | 44.25 | 71,906 |
| 2016-01-11 | Coughlin Timothy P (Chief Financial Officer) | Sale | 1,750 | 44.25 | 77,437 |
| 2016-01-11 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 1,750 | 44.25 | 77,437 |
| 2016-01-11 | Gorman Kevin Charles (President and CEO) | Sale | 3,750 | 44.17 | 165,637 |
| 2015-11-27 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 10,000 | 57.50 | 575,000 |
| 2015-11-27 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 10,000 | 5.76 | 57,600 |
| 2015-11-09 | Lippoldt Darin (Chief Legal Officer) | Sale | 23,761 | 52.92 | 1,257,432 |
| 2015-11-09 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 23,761 | 18.15 | 431,262 |
| 2015-10-16 | Gano Kyle (Chief Business Development Officer) | Sale | 25,000 | 47.77 | 1,194,250 |
| 2015-10-16 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 25,000 | 47.77 | 1,194,250 |
| 2015-10-16 | Bozigian Haig P. (Chief Development Officer) | Sale | 25,000 | 47.78 | 1,194,500 |
| 2015-10-16 | Coughlin Timothy P (Chief Financial Officer) | Sale | 25,000 | 47.78 | 1,194,500 |
| 2015-10-16 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 25,000 | 47.78 | 1,194,500 |
| 2015-10-16 | Gorman Kevin Charles (President and CEO) | Sale | 33,500 | 47.77 | 1,600,295 |
| 2015-09-18 | Lyons Gary A (Director) | Sale | 15,000 | 54.83 | 822,450 |
| 2015-07-20 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 19,646 | 55.00 | 1,080,530 |
| 2015-07-20 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 19,646 | 5.76 | 113,160 |
| 2015-07-20 | Coughlin Timothy P (Chief Financial Officer) | Sale | 20,000 | 55.00 | 1,100,000 |
| 2015-07-20 | Coughlin Timothy P (Chief Financial Officer) | Option Ex | 20,000 | 5.76 | 115,200 |
| 2015-07-20 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 11,250 | 55.00 | 618,750 |
| 2015-07-20 | Obrien Christopher Flint (Chief Medical Officer) | Option Ex | 11,250 | 5.76 | 64,800 |
| 2015-07-13 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 10,000 | 50.00 | 500,000 |
| 2015-07-13 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 10,000 | 5.76 | 57,600 |
| 2015-07-13 | Coughlin Timothy P (Chief Financial Officer) | Sale | 20,000 | 50.00 | 1,000,000 |
| 2015-07-13 | Coughlin Timothy P (Chief Financial Officer) | Option Ex | 20,000 | 5.76 | 115,200 |
| 2015-07-13 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 10,000 | 50.00 | 500,000 |
| 2015-07-13 | Obrien Christopher Flint (Chief Medical Officer) | Option Ex | 10,000 | 5.76 | 57,600 |
| 2015-06-23 | Mitchell W Thomas (Director) | Sale | 15,000 | 49.35 | 740,250 |
| 2015-06-23 | Mitchell W Thomas (Director) | Option Ex | 15,000 | 6.66 | 99,900 |
| 2015-06-08 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 10,000 | 45.00 | 450,000 |
| 2015-06-08 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 10,000 | 5.76 | 57,600 |
| 2015-06-08 | Coughlin Timothy P (Chief Financial Officer) | Sale | 60,000 | 45.08 | 2,704,800 |
| 2015-06-08 | Coughlin Timothy P (Chief Financial Officer) | Option Ex | 60,000 | 2.59 | 155,400 |
| 2015-06-08 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 10,000 | 45.00 | 450,000 |
| 2015-06-08 | Obrien Christopher Flint (Chief Medical Officer) | Option Ex | 10,000 | 5.76 | 57,600 |
| 2015-06-01 | Gano Kyle (See Remarks) | Sale | 38,230 | 42.19 | 1,612,923 |
| 2015-06-01 | Gano Kyle (See Remarks) | Option Ex | 38,230 | 4.17 | 159,610 |
| 2015-06-01 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 10,000 | 42.20 | 422,000 |
| 2015-06-01 | Obrien Christopher Flint (Chief Medical Officer) | Option Ex | 10,000 | 5.76 | 57,600 |
| 2015-05-11 | Pops Richard F (Director) | Option Ex | 15,000 | 4.76 | 71,400 |
| 2015-04-08 | Nevinny Corinne H (Director) | Option Ex | 15,000 | 4.76 | 71,400 |
| 2015-04-07 | Sherwin Stephen A (Director) | Option Ex | 15,000 | 4.76 | 71,400 |
| 2015-04-07 | Neurocrine Biosciences Inc (Director) | Option Ex | 15,000 | 4.76 | 71,400 |
| 2015-03-24 | Gorman Kevin Charles (President and CEO) | Sale | 40,000 | 41.53 | 1,661,200 |
| 2015-03-24 | Gorman Kevin Charles (President and CEO) | Option Ex | 40,000 | 2.59 | 103,600 |
| 2015-03-24 | Lyons Gary A (Director) | Sale | 30,000 | 41.53 | 1,245,900 |
| 2015-03-20 | Coughlin Timothy P (Chief Financial Officer) | Sale | 40,000 | 44.49 | 1,779,600 |
| 2015-03-20 | Coughlin Timothy P (Chief Financial Officer) | Option Ex | 40,000 | 2.59 | 103,600 |
| 2015-02-23 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 20,000 | 40.00 | 800,000 |
| 2015-02-23 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 20,000 | 5.76 | 115,200 |
| 2015-02-10 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 20,000 | 35.00 | 700,000 |
| 2015-02-10 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 20,000 | 5.76 | 115,200 |
| 2015-02-10 | Lyons Gary A (Director) | Option Ex | 7,500 | 4.76 | 35,700 |
| 2015-01-20 | Lyons Gary A (Director) | Option Ex | 7,500 | 4.76 | 35,700 |
| 2015-01-16 | Gano Kyle (Chief Business Dev Officer) | Sale | 1,625 | 30.80 | 50,050 |
| 2015-01-16 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 1,625 | 30.77 | 50,001 |
| 2015-01-16 | Bozigian Haig P. (Chief Development Officer) | Sale | 1,625 | 30.79 | 50,033 |
| 2015-01-16 | Coughlin Timothy P (Chief Financial Officer) | Sale | 1,750 | 30.81 | 53,917 |
| 2015-01-16 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 1,750 | 30.79 | 53,882 |
| 2015-01-16 | Gorman Kevin Charles (President and CEO) | Sale | 3,750 | 30.79 | 115,462 |
| 2015-01-13 | Gano Kyle (Chief Business Dev Officer) | Sale | 25,000 | 30.00 | 750,000 |
| 2015-01-13 | Gano Kyle (Chief Business Dev Officer) | Option Ex | 25,000 | 4.17 | 104,375 |
| 2015-01-13 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 20,000 | 30.00 | 600,000 |
| 2015-01-13 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 20,000 | 5.76 | 115,200 |
| 2015-01-13 | Mitchell W Thomas (Director) | Sale | 45,000 | 30.07 | 1,353,150 |
| 2015-01-13 | Mitchell W Thomas (Director) | Option Ex | 45,000 | 4.51 | 202,814 |
| 2015-01-12 | Gano Kyle (Chief Business Dev Officer) | Sale | 1,250 | 28.41 | 35,512 |
| 2015-01-12 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 1,625 | 28.38 | 46,117 |
| 2015-01-12 | Bozigian Haig P. (Chief Development Officer) | Sale | 1,625 | 28.45 | 46,231 |
| 2015-01-12 | Coughlin Timothy P (Chief Financial Officer) | Sale | 1,750 | 28.37 | 49,647 |
| 2015-01-12 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 1,750 | 28.41 | 49,717 |
| 2015-01-12 | Gorman Kevin Charles (President and CEO) | Sale | 3,750 | 28.43 | 106,612 |
| 2015-01-08 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 30,000 | 27.39 | 821,700 |
| 2015-01-08 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 30,000 | 2.59 | 77,700 |
| 2015-01-08 | Bozigian Haig P. (Chief Development Officer) | Sale | 30,000 | 27.30 | 819,150 |
| 2015-01-08 | Bozigian Haig P. (Chief Development Officer) | Option Ex | 30,000 | 2.59 | 77,700 |
| 2015-01-08 | Coughlin Timothy P (Chief Financial Officer) | Sale | 10,000 | 27.25 | 272,500 |
| 2015-01-08 | Coughlin Timothy P (Chief Financial Officer) | Option Ex | 10,000 | 2.59 | 25,900 |
| 2015-01-08 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 55,000 | 27.24 | 1,498,200 |
| 2015-01-08 | Obrien Christopher Flint (Chief Medical Officer) | Option Ex | 55,000 | 2.59 | 142,450 |
| 2015-01-08 | Gorman Kevin Charles (President and CEO) | Sale | 25,000 | 27.39 | 684,750 |
| 2015-01-08 | Gorman Kevin Charles (President and CEO) | Option Ex | 25,000 | 2.59 | 64,750 |
| 2015-01-05 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 2,500 | 22.76 | 56,900 |
| 2015-01-05 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 2,500 | 5.12 | 12,800 |
| 2015-01-05 | Bozigian Haig P. (Chief Development Officer) | Sale | 2,500 | 22.76 | 56,900 |
| 2015-01-05 | Bozigian Haig P. (Chief Development Officer) | Option Ex | 2,500 | 5.12 | 12,800 |
| 2015-01-02 | Mitchell W Thomas (Director) | Sale | 8,000 | 22.79 | 182,320 |
| 2015-01-02 | Mitchell W Thomas (Director) | Option Ex | 8,000 | 4.76 | 38,080 |
Insider trading activities including stock purchases, stock sales, and option exercises
of NBIX listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Neurocrine Biosciences Inc (symbol NBIX,
CIK number 914475) see
the Securities and Exchange Commission (SEC) website.